Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | HRAS G13R |
| Therapy | Darlifarnib |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS G13R | head and neck squamous cell carcinoma | sensitive | Darlifarnib | Preclinical - Pdx | Actionable | In a preclinical study, Darlifarnib (KO-2806) inhibited tumor growth more efficiently than Zarnestra (tipifarnib) and induced tumor regression in a patient-derived xenograft (PDX) model of head and neck squamous cell carcinoma harboring HRAS G13R (PMID: 41661652). | 41661652 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41661652) | The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition. | Full reference... |